Connect your AI

iRadimed IRMD Shipments in-transit

Other financials

Income statement

Revenue$22.0M+12.6%

Gross profit$16.8M+13.3%

Operating income$7.2M+33.2%

Net income$5.8M+24.1%

EPS (diluted)$0.45+21.6%

Balance sheet

Cash & equivalents$56.4M+12.0%

Total debt$59.2K-96.9%

Total equity$98.5M+9.4%

Total assets$114.4M+12.4%

Cash flow

Operating cash flow$8.3M+93.2%

CapEx$403.0K-89.1%

Free cash flow$7.9M+1,226%

Valuation

Market cap$1.21B+63.4%

P/E51.3×+13.8×

P/S14×+4.2×

Profitability

Gross margin76.8%-0.1pp

Operating margin32.4%+2.3pp

Net margin27.4%+1.0pp

FCF margin28.4%+8.9pp

Returns & leverage

Return on equity25%+1.2pp

Debt / equity0×0.0×

Current ratio7.1×-1.7×

Where this comes from

Reported directly by iRadimed in its filing.

Tagged under the XBRL concept irmd:ShipmentsInTransit.

The official record: iRadimed’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about iRadimed's shipments in-transit.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is iRadimed's shipments in-transit?: iRadimed (IRMD) reported shipments in-transit of $231K in Q1 2026.